Does the media prefer BLCO or ZBH?

In the previous week, Bausch + Lomb and Bausch + Lomb both had 17 articles in the media. Zimmer Biomet's average media sentiment score of 0.90 beat Bausch + Lomb's score of 0.31 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zimmer Biomet 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, SOLV or BLCO?

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.26B 1.80 $1.56B $8.16 10.50 Bausch + Lomb $5.10B 1.18 -$360M -$0.48 N/A

Is SOLV or BLCO more profitable?

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Bausch + Lomb -3.21% 4.14% 1.93%

Does the media refer more to SOLV or BLCO?

In the previous week, Bausch + Lomb had 6 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Bausch + Lomb and 11 mentions for Solventum. Solventum's average media sentiment score of 0.78 beat Bausch + Lomb's score of 0.31 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, BLCO or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch + Lomb $5.10B 1.18 -$360M -$0.48 N/A Smith & Nephew SNATS $6.16B 2.16 $625M N/A N/A

Does the media prefer BLCO or SNN?

In the previous week, Bausch + Lomb had 12 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for Bausch + Lomb and 5 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.68 beat Bausch + Lomb's score of 0.31 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PEN or BLCO more profitable?

Penumbra has a net margin of 10.67% compared to Bausch + Lomb's net margin of -3.21%. Penumbra's return on equity of 10.50% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Bausch + Lomb -3.21% 4.14% 1.93%

Does the media refer more to PEN or BLCO?

In the previous week, Bausch + Lomb had 2 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Bausch + Lomb and 15 mentions for Penumbra. Penumbra's average media sentiment score of 0.92 beat Bausch + Lomb's score of 0.31 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, GKOS or BLCO?

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.35 -$187.69M -$3.25 N/A Bausch + Lomb $5.10B 1.18 -$360M -$0.48 N/A

Is GKOS or BLCO more profitable?

Bausch + Lomb has a net margin of -3.21% compared to Glaukos' net margin of -30.68%. Bausch + Lomb's return on equity of 4.14% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% Bausch + Lomb -3.21% 4.14% 1.93%

Does the media refer more to GKOS or BLCO?

In the previous week, Glaukos had 15 more articles in the media than Bausch + Lomb. MarketBeat recorded 32 mentions for Glaukos and 17 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.72 beat Bausch + Lomb's score of 0.31 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 11 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bausch + Lomb (BLCO) Competitors

$16.89 -0.02 (-0.10%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$16.90 +0.01 (+0.07%)

As of 07/31/2026 07:34 PM Eastern

Compare

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS).

How does Bausch + Lomb compare to Zimmer Biomet?

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Bausch + Lomb has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

In the previous week, Bausch + Lomb and Bausch + Lomb both had 17 articles in the media. Zimmer Biomet's average media sentiment score of 0.90 beat Bausch + Lomb's score of 0.31 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb currently has a consensus target price of $18.67, indicating a potential upside of 10.50%. Zimmer Biomet has a consensus target price of $102.00, indicating a potential upside of 8.28%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, research analysts plainly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.24

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.47

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -3.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Zimmer Biomet	9.05%	13.24%	7.28%

Summary

Zimmer Biomet beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Solventum has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

11.1% of Bausch + Lomb shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bausch + Lomb had 6 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Bausch + Lomb and 11 mentions for Solventum. Solventum's average media sentiment score of 0.78 beat Bausch + Lomb's score of 0.31 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum currently has a consensus target price of $86.00, indicating a potential upside of 0.36%. Bausch + Lomb has a consensus target price of $18.67, indicating a potential upside of 10.50%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Bausch + Lomb	-3.21%	4.14%	1.93%

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.80	$1.56B	$8.16	10.50
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A

Summary

Solventum beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Bausch + Lomb (NYSE:BLCO) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bausch + Lomb had 12 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for Bausch + Lomb and 5 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.68 beat Bausch + Lomb's score of 0.31 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A
Smith & Nephew SNATS	$6.16B	2.16	$625M	N/A	N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -3.21%. Bausch + Lomb's return on equity of 4.14% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Smith & Nephew SNATS	N/A	N/A	N/A

Bausch + Lomb currently has a consensus target price of $18.67, suggesting a potential upside of 10.50%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential downside of 1.92%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, research analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Bausch + Lomb has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Bausch + Lomb and Smith & Nephew SNATS tied by winning 7 of the 14 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Penumbra (NYSE:PEN) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Penumbra presently has a consensus target price of $367.07, suggesting a potential upside of 14.21%. Bausch + Lomb has a consensus target price of $18.67, suggesting a potential upside of 10.50%. Given Penumbra's higher probable upside, research analysts clearly believe Penumbra is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29

Penumbra has a net margin of 10.67% compared to Bausch + Lomb's net margin of -3.21%. Penumbra's return on equity of 10.50% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Bausch + Lomb	-3.21%	4.14%	1.93%

88.9% of Penumbra shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Penumbra has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.02	$177.69M	$4.07	78.97
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A

Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

In the previous week, Bausch + Lomb had 2 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Bausch + Lomb and 15 mentions for Penumbra. Penumbra's average media sentiment score of 0.92 beat Bausch + Lomb's score of 0.31 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Penumbra beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Glaukos (NYSE:GKOS) and Bausch + Lomb (NYSE:BLCO) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Bausch + Lomb has a net margin of -3.21% compared to Glaukos' net margin of -30.68%. Bausch + Lomb's return on equity of 4.14% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Bausch + Lomb	-3.21%	4.14%	1.93%

Glaukos presently has a consensus target price of $177.33, suggesting a potential upside of 6.49%. Bausch + Lomb has a consensus target price of $18.67, suggesting a potential upside of 10.50%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29

Glaukos has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

In the previous week, Glaukos had 15 more articles in the media than Bausch + Lomb. MarketBeat recorded 32 mentions for Glaukos and 17 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.72 beat Bausch + Lomb's score of 0.31 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	11 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.35	-$187.69M	-$3.25	N/A
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A

Summary

Glaukos beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.03B	$5.58B	$6.86B	$23.66B
Dividend Yield	N/A	1.79%	2.59%	4.21%
P/E Ratio	-35.19	23.11	282.30	31.00
Price / Sales	1.18	56.88	564.98	81.82
Price / Cash	10.14	32.53	28.60	18.73
Price / Book	0.92	6.29	10.92	4.76
Net Income	-$360M	$151.15M	$3.49B	$1.07B
7 Day Performance	3.82%	0.96%	-0.64%	-0.34%
1 Month Performance	-1.97%	-3.50%	-5.24%	-0.53%
1 Year Performance	24.95%	2.31%	61.98%	19.19%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.1912 of 5 stars	$16.89 -0.1%	$18.67 +10.5%	+24.9%	$6.03B	$5.10B	N/A	13,000
ZBH Zimmer Biomet	3.1926 of 5 stars	$91.35 +1.9%	$100.70 +10.2%	+3.9%	$17.67B	$8.23B	23.73	17,000	Positive News Upcoming Earnings
SOLV Solventum	2.9753 of 5 stars	$78.02 +1.0%	$81.91 +5.0%	+19.5%	$13.51B	$8.33B	9.56	20,000	Positive News Upcoming Earnings
SNN Smith & Nephew SNATS	1.9857 of 5 stars	$30.53 +2.6%	$30.93 +1.3%	+2.1%	$12.92B	$6.16B	N/A	16,988	News Coverage Upcoming Earnings Gap Down
PEN Penumbra	2.9928 of 5 stars	$318.60 +0.2%	$360.33 +13.1%	+32.5%	$12.54B	$1.45B	73.41	4,700	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Which has more volatility and risk, BLCO or ZBH?

Does the media prefer BLCO or ZBH?

Do analysts prefer BLCO or ZBH?

Do insiders & institutionals hold more shares of BLCO or ZBH?

Which has preferable valuation and earnings, BLCO or ZBH?

Is BLCO or ZBH more profitable?

Summary

How does Bausch + Lomb compare to Solventum?

Which has more risk and volatility, SOLV or BLCO?

Do institutionals and insiders believe in SOLV or BLCO?

Does the media refer more to SOLV or BLCO?

Do analysts recommend SOLV or BLCO?

Is SOLV or BLCO more profitable?

Which has stronger earnings & valuation, SOLV or BLCO?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Do insiders and institutionals hold more shares of BLCO or SNN?

Does the media prefer BLCO or SNN?

Which has stronger earnings and valuation, BLCO or SNN?

Is BLCO or SNN more profitable?

Do analysts prefer BLCO or SNN?

Which has more risk and volatility, BLCO or SNN?

Summary

How does Bausch + Lomb compare to Penumbra?

Do analysts recommend PEN or BLCO?

Is PEN or BLCO more profitable?

Do insiders & institutionals believe in PEN or BLCO?

Which has better valuation & earnings, PEN or BLCO?

Which has more volatility & risk, PEN or BLCO?

Does the media refer more to PEN or BLCO?

Summary

How does Bausch + Lomb compare to Glaukos?

Is GKOS or BLCO more profitable?

Do analysts rate GKOS or BLCO?

Which has more risk and volatility, GKOS or BLCO?

Does the media refer more to GKOS or BLCO?

Do institutionals & insiders believe in GKOS or BLCO?

Which has preferable valuation & earnings, GKOS or BLCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools